文献速递白血病造血干细胞移植与细胞治疗

PD-L1过表达对CLL-1 CAR-T抗急性髓系白血病的影响研究

[Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

本研究构建稳定表达PD-L1的THP-1单克隆细胞株,与CLL-1 CAR-T细胞共培养,发现PD-L1过表达抑制CAR-T细胞杀伤、细胞因子释放和增殖,为PD-1/PD-L1通路调控提供理论依据。

要点

  • 成功构建稳定表达PD-L1的THP1-PDL1单克隆细胞株。
  • 效靶比10∶1时PD-L1过表达降低CLL-1 CAR-T杀伤效率。
  • PD-L1过表达抑制CLL-1 CAR-T细胞因子释放和增殖。

核心结论

  • PD-L1过表达对CLL-1 CAR-T抗AML产生不利影响。

研究设计与样本

  • 体外研究:构建PD-L1慢病毒并筛选THP1-PDL1单克隆细胞株,与CLL-1 CAR-T共培养。
  • 以THP-1或THP1-PDL1为靶细胞,用LDH法、CBA法、CFSE法评价功能。

主要发现

  • 效靶比10∶1时,CLL-1 CAR-T对THP1-PDL1杀伤效率(15.70±9.90)%低于对THP-1的(51.95±2.52)%,P<0.05。
  • 与THP1-PDL1共培养较THP-1共培养,IFN-γ为(115.66±3.13)pg/ml对(1708.16±26.76)pg/ml,P<0.05。
  • IL-6为(17.37±0.72)pg/ml对(124.92±4.26)pg/ml,P<0.05;IL-10为(5.69±0.13)pg/ml对(124.12±3.02)pg/ml,P<0.05。
  • PD-L1过表达同时抑制CLL-1 CAR-T细胞增殖。

临床怎么用

  • 提示PD-1/PD-L1通路可能参与调控CLL-1 CAR-T抗AML功能。
  • 为后续通过PD-1/PD-L1通路改善CLL-1 CAR-T疗效提供体外依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effects of programmed death receptor ligand 1(PD-L1)on CLL-1 CAR-T against acute myeloid leukemia(AML). Methods: In this experiment, the PD-L1 expression vector was constructed, and then the lentivirus vector was packaged by three-plasmid packaging system. THP-1 monoclonal cell lines stably expressing PD-L1 were set up. The CLL-1 CAR-T was developed by our team, as the effector cell for co-culture with the THP-1 or THP1-PDL1 cell lines, respectively. Then, the LDH was tested using the kit, the supernatant cytokine was detected by CBA, and the CLL-1 CAR-T cell proliferation was demonstrated by flow cytometry(FCM)with CSFE labeled. Results: ①The PD-L1 lentivirus vector was successfully constructed, and monoclonal cell lines of THP-1 with stable PD-L1 was set up and verified by FCM and PCR. ②The overexpression of PD-L1 inhibited CLL-1 CAR-T's ability to lyse THP-1 cells(E∶F ratio 10∶1); the killing efficiency of CLL-1 CAR-T on THP1-PDL1 cells was lower than that of THP-1 cells[(15.70±9.90)% vs(51.95 ± 2.52)%, P<0.05]. ③The overexpression of PD-L1 decrease the release of cytokine[THP1-PDL1 group vs THP-1 group: IFN-γ(115.66±3.13)pg/ml vs(1708.16 ± 26.76)pg/ml, P<0.05; IL-6(17.37±0.72)pg/ml vs(124.92±4.26)pg/ml, P<0.05; IL-10(5.69±0.13)pg/ml vs(124.12±3.02)pg/ml, P<0.05]. Additionally, the proliferation of CLL-1 CAR-T was also inhibited. Conclusion: Monoclonal cell lines of THP-1 with stable PD-L1 expression were successfully constructed, and the adverse effect of PD-L1 overexpression on CLL-1 CAR-T anti-AML was confirmed, which provided a theoretical basis for the regulation of CLL-1CAR-T through the PD-1/PD-L1 pathway. 目的: 探讨程序性死亡受体配体1(PD-L1)对CLL-1 CAR-T细胞抗急性髓系白血病(AML)作用的影响。 方法: 通过构建PD-L1表达载体、制备慢病毒、转导、单克隆筛选技术获得稳定表达PD-L1的THP-1单克隆细胞株(THP1-PDL1),然后以前期制备的CLL-1 CAR-T细胞为效应细胞,以THP-1、THP1-PDL1单克隆细胞株作为靶细胞,分别通过LDH检测、CBA法、CFSE法评价PD-L1过表达对CLL-1 CAR-T细胞裂解功能、炎性因子释放、细胞增殖等功能的影响。 结果: ①成功制备了PD-L1慢病毒,并筛选获得了稳定表达PD-L1的THP1-PDL1单克隆细胞株,流式细胞术及PCR验证成功。②PD-L1过表达抑制了CLL-1 CAR-T细胞裂解THP-1细胞的能力;效靶比为10∶1时,CLL-1 CAR-T细胞对THP1-PDL1细胞的杀伤效率明显低于对THP-1细胞的杀伤效率[(15.70±9.90)%对(51.95±2.52)%,P<0.05]。③PD-L1过表达减弱了CLL-1 CAR-T细胞释放细胞因子的能力[与THP1-PDL1细胞共培养时对与THP-1细胞共培养时:IFN-γ(115.66±3.13)pg/ml对(1708.16±26.76)pg/ml,P<0.05;IL-6(17.37±0.72)pg/ml对(124.92±4.26)pg/ml,P<0.05;IL-10(5.69±0.13)pg/ml对(124.12±3.02)pg/ml,P<0.05];同时抑制了CLL-1 CAR-T细胞的增殖能力。 结论: 成功构建了表达PD-L1的THP1-PDL1单克隆细胞株,同时证实了PD-L1过表达对CLL-1 CAR-T细胞抗AML的不利的影响,为通过PD-1/PD-L1通路调控CLL-1 CAR-T细胞功能提供了一定的理论基础。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lin GQ, Zhang YM, Kang LQ, et al. [Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33190440. doi:10.3760/cma.j.issn.0253-2727.2020.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。